The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 15: 2362 - 2371

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.15.011

Clinical Research

The relationship between the triglyceride⁃glucose index and its modified index and colorectal cancer： A prospective cohort study

  • Yi LU ,
  • Shilong DAI ,
  • Mingjun WANG ,
  • Jing ZHOU ,
  • Junying HAO ,
  • Chen ZHENG ,
  • Xinbo XU ,
  • Shan DING ,
  • Qingsong ZHANG
Expand
  • *.Department of General Surgery，Kailuan General Hospital Affiliated to North China University of Science and Technology，Tangshan 063000，Hebei，China
    *.Graduate School of North China University of Science and Technology，Tangshan 063000，Hebei，China

Received date: 2025-04-29

  Online published: 2025-08-11

Fold

Abstract

Objective To investigate the association between the TyG index， its modified variants， and the risk of developing colorectal cancer （CRC）. Methods This study included a total of 93，177 participants from the 2006 Kailuan Group health examination cohort. Participants were categorized into four quartiles （Q1-Q4） according to their TyG and modified TyG indices. Follow-up began at the baseline examination， with incident CRC as the primary outcome. Participants were censored at the time of CRC diagnosis， death， or the end of the study， whichever occurred first. The dose-response relationship between TyG and its modified indices and the risk of CRC was evaluated using restricted cubic splines （RCS） in conjunction with Cox proportional hazards regression models， yielding hazard ratios （HRs） and 95% confidence intervals （CIs）. To compare the strength of associations between TyG and its modified versions （TyG-BMI， TyG-WC， TyG-WHR， TyG-WHtR， TyG-WWI） and CRC risk， HRs for CRC per one standard deviation increase in each index were calculated and compared. Results Both the TyG index and its modified variants demonstrated a significant dose-response relationship with the risk of CRC incidence. Specifically， for the TyG index， each 1-standard deviation （SD） increase was associated with a 1.17-fold （95%CI： 1.09 ~ 1.27） higher risk of CRC. Compared with the first quartile （Q1）， the third quartile （Q3） and fourth quartile （Q4） exhibited a 1.25-fold （95%CI： 1.01 ~ 1.55） and 1.26-fold （95%CI： 1.01 ~ 1.57） increased risk， respectively. For TyG-BMI， each 1-SD increase was linked to a 1.20-fold （95%CI： 1.07 ~ 1.35） elevated CRC risk. Compared with Q1， Q3 and Q4 showed a 1.32-fold （95%CI： 1.06 ~ 1.64） and 1.51-fold （95%CI： 1.21 ~ 1.88） increase， respectively. Regarding TyG-WC， each 1-SD increment was associated with a 1.22-fold （95%CI： 1.13 ~ 1.32） higher CRC risk， with Q3 and Q4 showing a 1.35-fold （95%CI： 1.08 ~ 1.70） and 1.56-fold （95%CI： 1.24 ~ 1.96） increased risk compared to Q1. For TyG-WHtR， each 1-SD increase was associated with a 1.24-fold （95%CI： 1.08-1.42） higher CRC risk. Compared with Q1， Q2， Q3， and Q4 demonstrated a 1.31-fold （95%CI： 1.03 ~ 1.66）， 1.55-fold （95%CI： 1.23 ~ 1.95）， and 1.60-fold （95%CI： 1.27 ~ 2.02） increase， respectively. In the case of TyG-WHR， each 1-SD increase was associated with a 1.19-fold （95%CI： 1.10 ~ 1.29） higher CRC risk， with Q4 showing a 1.42-fold （95%CI： 1.14 ~ 1.77） increased risk compared to Q1. Finally， for TyG-WWI， each 1-SD increase was associated with a 1.22-fold （95%CI： 1.13 ~ 1.32） elevated CRC risk， with both Q3 and Q4 showing a 1.58-fold increase （Q3： 95%CI： 1.26 ~ 1.98； Q4： 95%CI： 1.25 ~ 1.99）. Stratified analyses by sex and age consistently revealed significant associations between the TyG index and its modified variants and CRC risk. Furthermore， these indices were independently associated with the incidence of both colon cancer and rectal cancer. Conclusions （1） Elevated levels of the TyG index and its modified variants are independent risk factors for CRC. （2） Both the TyG index and its modified forms demonstrate a significant dose-response association with the incidence of CRC. （3） Among the modified TyG indices， TyG-WWI， TyG-WHtR， TyG-BMI， TyG-WC， and TyG-WHR showed stronger correlations with CRC risk compared to the original TyG index.

Key words： colorectal cancer; insulin resistance; influencing factors analysis

Cite this article

Yi LU , Shilong DAI , Mingjun WANG , Jing ZHOU , Junying HAO , Chen ZHENG , Xinbo XU , Shan DING , Qingsong ZHANG . The relationship between the triglyceride⁃glucose index and its modified index and colorectal cancer： A prospective cohort study[J]. The Journal of Practical Medicine, 2025 , 41(15) : 2362 -2371 . DOI: 10.3969/j.issn.1006-5725.2025.15.011

References

[1] ABBASPOUR E， KARIMZADHAGH S， MONSEF A， et al. Application of radiomics for preoperative prediction of lymph node metastasis in colorectal cancer： A systematic review and meta-analysis［J］. Int J Surg， 2024， 110（6）： 3795-3813. doi:10.1097/js9.0000000000001239
[2] WANG S Y， ZHANG W S， JIANG C Q， et al. Association of novel and conventional obesity indices with colorectal cancer risk in older Chinese： A 14-year follow-up of the Guangzhou Biobank Cohort Study［J］. BMC Cancer， 2023， 23（1）： 286. doi:10.1186/s12885-023-10762-0
[3] WU P N， LIU J L， FANG M J， et al. Global trends in colorectal cancer and metabolic syndrome research： A bibliometric and visualization analysis［J］. Int J Surg， 2024， 110（6）： 3723-3733. doi:10.1097/js9.0000000000001342
[4] LI W， LIU T， QIAN L， et al. Insulin resistance and inflammation mediate the association of abdominal obesity with colorectal cancer risk［J］. Front Endocrinol （Lausanne）， 2022， 13： 983160. doi:10.3389/fendo.2022.983160
[5] LUO Y， LIU L， LIU M， et al. Relationship Between Body Composition and Insulin Resistance Evaluated by the TyG Index： A Retrospective Study Among Chinese Population［J］. Clin Endocrinol （Oxf）， 2025， 102（3）： 264-272. doi:10.1111/cen.15171
[6] MIAO H， ZHOU Z， YANG S， et al. The association of triglyceride-glucose index and related parameters with hypertension and cardiovascular risk： A cross-sectional study［J］. Hypertens Res， 2024， 47（4）： 877-886. doi:10.1038/s41440-023-01502-9
[7] YANG C， SONG Y， WANG X， et al. Association of hypertension with the triglyceride-glucose index and its associated indices in the Chinese population： A 6-year prospective cohort study［J］. J Clin Hypertens （Greenwich）， 2024， 26（1）： 53-62. doi:10.1111/jch.14758
[8] 周静， 贾建国， 林艺鑫， 等. 不同代谢肥胖表型与女性乳腺癌发病风险关联：一项前瞻性队列研究［J］. 中国全科医学， 2024， 27（02）： 150-155.
[9] LIU T， ZHANG Q， WANG Y， et al. Association between the TyG index and TG/HDL-C ratio as insulin resistance markers and the risk of colorectal cancer［J］. BMC Cancer， 2022， 22（1）： 1007. doi:10.1186/s12885-022-10100-w
[10] SON M， MOON S Y， KOH M， et al. Association between Surrogate Markers of Insulin Resistance and the Incidence of Colorectal Cancer in Korea： A Nationwide Population-Based Study［J］. J Clin Med， 2024， 13（6）：1628. doi:10.3390/jcm13061628
[11] ZHA B， CAI A， WANG G. Relationship between obesity indexes and triglyceride glucose index with gastrointestinal cancer among the US population［J］. Prev Med Rep， 2024， 43： 102760. doi:10.1016/j.pmedr.2024.102760
[12] LUO L， LIU Z， GAN Q， et al. Relationships of triglyceride-glucose-related indices with colorectal cancer incidence and mortality in an American population： A dose-response meta-analysis and cohort study［J］. Lipids Health Dis， 2025， 24（1）： 151. doi:10.1186/s12944-025-02574-x
[13] NEWCOMB P A， ZHENG Y， CHIA V M， et al. Estrogen plus progestin use， microsatellite instability， and the risk of colorectal cancer in women［J］. Cancer Res， 2007， 67（15）： 7534-7539. doi:10.1158/0008-5472.can-06-4275
[14] YAN S， WANG D， JIA Y. Comparison of insulin resistance-associated parameters in US adults： A cross-sectional study［J］. Hormones （Athens）， 2023， 22（2）： 331-341. doi:10.1007/s42000-023-00448-4
[15] JIN X， QIU T， LI L， et al. Pathophysiology of obesity and its associated diseases［J］. Acta Pharm Sin B， 2023， 13（6）： 2403-2424. doi:10.1016/j.apsb.2023.01.012
[16] OH Y S， BAE G D， BAEK D J， et al. Fatty Acid-Induced Lipotoxicity in Pancreatic Beta-Cells During Development of Type 2 Diabetes［J］. Front Endocrinol （Lausanne）， 2018， 9： 384. doi:10.3389/fendo.2018.00384
[17] 李晓彤. TyG相关指数、肥胖指数和脂质比对中老年人群糖尿病发病的预测价值［D］. 长春：吉林大学， 2023.
[18] 阳静， 朱晨燕， 袁璐， 等. TyG指数及TyG-肥胖联合指数与缺血性心脏病发生风险的关联研究［J］. 四川大学学报（医学版）， 2024， 55（5）： 1123-1132.
[19] ASIRI A， QARNI A AL， BAKILLAH A. The Interlinking Metabolic Association between Type 2 Diabetes Mellitus and Cancer： Molecular Mechanisms and Therapeutic Insights［J］. Diagnostics （Basel）， 2024， 14（19）：2132. doi:10.3390/diagnostics14192132
[20] HAEUSLER R A， MCGRAW T E， Accili D. Biochemical and cellular properties of insulin receptor signalling［J］. Nat Rev Mol Cell Biol， 2018， 19（1）： 31-44. doi:10.1038/nrm.2017.89
[21] M?INEA C P， SANO H， KANE S， et al. AS160， the Akt substrate regulating GLUT4 translocation， has a functional Rab GTPase-activating protein domain［J］. Biochem J， 2005， 391（Pt 1）： 87-93. doi:10.1042/bj20050887
[22] ZHANG A M Y， WELLBERG E A， KOPP J L， et al. Hyperinsulinemia in Obesity， Inflammation， and Cancer［J］. Diabetes Metab J， 2021， 45（3）： 285-311. doi:10.4093/dmj.2020.0250
[23] GLAVIANO A， FOO A S C， LAM H Y， et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer［J］. Mol Cancer， 2023， 22（1）： 138. doi:10.1186/s12943-023-01827-6
[24] CHEN X， LIANG H， SONG Q， et al. Insulin promotes progression of colon cancer by upregulation of ACAT1［J］. Lipids Health Dis， 2018， 17（1）： 122. doi:10.1186/s12944-018-0773-x
[25] NAM S Y， LEE E J， KIM K R， et al. Effect of obesity on total and free insulin-like growth factor （IGF）-1， and their relationship to IGF-binding protein （BP）-1， IGFBP-2， IGFBP-3， insulin， and growth hormone［J］. Int J Obes Relat Metab Disord， 1997， 21（5）： 355-359. doi:10.1038/sj.ijo.0800412
[26] AARONSON S A. Growth factors and cancer［J］. Science， 1991， 254（5035）： 1146-1153. doi:10.1126/science.1659742
[27] ERARSLAN E， TURKAY C， KOKTENER A， et al. Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia［J］. Dig Dis Sci， 2009， 54（4）： 862-868. doi:10.1007/s10620-008-0440-6
[28] SHI X， JIANG A， QIU Z， et al. Novel perspectives on the link between obesity and cancer risk： From mechanisms to clinical implications［J］. Front Med， 2024， 18（6）： 945-968. doi:10.1007/s11684-024-1094-2
[29] KARCZEWSKI J， ?LEDZI?SKA E， BATURO A， et al. Obesity and inflammation［J］. Eur Cytokine Netw， 2018， 29（3）： 83-94. doi:10.1684/ecn.2018.0415
Options
Outlines

/

〈 〉